US2011052601A1PendingUtilityA1

Compositions comprising anti-icam-1 antibodies

Assignee: UNIV SOUTH FLORIDAPriority: Mar 11, 1999Filed: Feb 20, 2009Published: Mar 3, 2011
Est. expiryMar 11, 2019(expired)· nominal 20-yr term from priority
A61P 31/12A61P 11/00C12N 15/1138C12N 2310/11C12N 2320/32C12N 15/111
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

There is provided a method of preventing a respiratory infection by administering an effective amount of an agent for regulating ICAM-1 expression. Also provided is a composition for the prevention of respiratory infection including an agent which regulates ICAM expression. method of preventing RSV infection by administering an effective amount of an agent that interferes with the binding of RSV to ICAM-1. A method of preventing RSV infection by administering an effective amount of an agent that down regulates the expression of ICAM-1, thereby decreasing RSV binding to ICAM-1 is also provided. There is provided a method of treating RSV infection by administering an effective amount of an agent for down regulating ICAM-1 expression. A method of blocking RSV-ICAM-1 interaction by administering an effective amount of agents for blocking ICAM sites of binding is provided. Also provided is a compound for blocking RSV-ICAM-1 interaction including an agent for blocking ICAM sites of binding.

Claims

exact text as granted — not AI-modified
1 . A method of preventing a respiratory syncytial virus (RSV) infection, comprising administering an effective amount of an antibody to ICAM-1 to a patient sufficient to prevent the RSV infection. 
     
     
         2 . The method according to  claim 1 , wherein the antibody blocks the RSV-F binding site on ICAM-1. 
     
     
         3 . The method according to  claim 1 , wherein the patient is human. 
     
     
         4 . The method according to  claim 1 , wherein said administering comprises administering the antibody to airway epithelial cells. 
     
     
         5 . The method according to  claim 1 , wherein said administering comprises administering the antibody orally. 
     
     
         6 . The method according to  claim 1 , wherein said administering comprises administering the antibody intranasally. 
     
     
         7 . The method according to  claim 1 , wherein said administering comprises administering the antibody by inhalation. 
     
     
         8 . The method according to  claim 1 , wherein said administering comprises injecting the antibody.

Join the waitlist — get patent alerts

Track US2011052601A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.